Trial Outcomes & Findings for Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (NCT NCT03030417)

Last Updated: 2024-12-10

Results Overview

Maximum tolerated dose (MTD) of LMP744 administered intravenously (IV) daily for 5 days (QD x 5) schedule in participants with refractory solid tumors and lymphomas. The MTD is the dose level at which no more than 1 in 6 participants experience dose-limiting toxicity (DLT), and the dose below that at which ≥ 2 (of ≤ 6) participants have DLT as a result of the drug. A DLT is Grade ≥3 non-hematologic toxicity except Grade 3 fatigue lasting ≤ 7 days. Grade 4 hematological toxicity if it meets the following criteria: Lymphopenia (any grade) will not be considered dose limiting for all participants; Anemia: Grade 4 anemia will be considered dose limiting. Any neurotoxicity Grade ≥2 that is not reversible to a Grade ≤1 within 2 weeks. Any non-hematologic Grade 2 toxicity that does not resolve to Grade ≤1 or baseline within 14 days despite adequate treatment, except for alopecia.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

36 participants

Primary outcome timeframe

Cycle 1 (28 days)

Results posted on

2024-12-10

Participant Flow

Participant milestones

Participant milestones
Measure	Treatment (Trmt) Assignment (Assign.) 1: LMP744 (MJ-III65 Hydrochloride) 6mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 6mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Enrolled But Not Treated Participant was enrolled but not treated.
Dose Escalation STARTED	1	1	3	1	1	9	0	0	10	1	0
Dose Escalation Restaging	1	1	0	1	1	9	0	0	7	1	0
Dose Escalation Pharmacokinetic Sampling	1	1	3	1	1	9	0	0	4	0	0
Dose Escalation Tumor Biopsies	0	0	0	0	0	0	0	0	0	0	0
Dose Escalation COMPLETED	1	1	3	1	1	9	0	0	10	1	0
Dose Escalation NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0
Dose Expansion STARTED	0	0	0	0	0	5	2	1	0	0	1
Dose Expansion Restaging	0	0	0	0	0	2	2	1	0	0	0
Dose Expansion Pharmacokinetic Sampling	0	0	0	0	0	0	0	0	0	0	0
Dose Expansion Tumor Biopsies	0	0	0	0	0	5	2	1	0	0	1
Dose Expansion COMPLETED	0	0	0	0	0	5	2	1	0	0	0
Dose Expansion NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Treatment (Trmt) Assignment (Assign.) 1: LMP744 (MJ-III65 Hydrochloride) 6mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 6mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 8: LMP744 (MJ-III65 Hydrochloride) 360mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 360mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle. No participants were enrolled in this group.	Treatment Assignment 9: LMP744 (MJ-III65 Hydrochloride) 500mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 500mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle. No participants were enrolled in this group.	Enrolled But Not Treated Participant was enrolled but not treated.
Dose Expansion Disease progression before treatment	0	0	0	0	0	0	0	0	0	0	0	0	1

Baseline Characteristics

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment (Trmt) Assignment (Assign.) 1: LMP744 (MJ-III65 Hydrochloride) 6mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 6mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=14 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 n=2 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=10 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Enrolled But Not Treated n=1 Participants Participant was enrolled but not treated.	Total n=36 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	7 Participants n=8 Participants	2 Participants n=8 Participants	1 Participants n=24 Participants	6 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	21 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	7 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	4 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	15 Participants n=42 Participants
Age, Continuous	49 years STANDARD_DEVIATION 0 • n=5 Participants	79 years STANDARD_DEVIATION 0 • n=7 Participants	55.67 years STANDARD_DEVIATION 8.96 • n=5 Participants	81 years STANDARD_DEVIATION 0 • n=4 Participants	39 years STANDARD_DEVIATION 0 • n=21 Participants	62.57 years STANDARD_DEVIATION 12.18 • n=8 Participants	49 years STANDARD_DEVIATION 19.8 • n=8 Participants	46 years STANDARD_DEVIATION 0 • n=24 Participants	61.1 years STANDARD_DEVIATION 8.96 • n=42 Participants	72 years STANDARD_DEVIATION 0 • n=42 Participants	43 years STANDARD_DEVIATION 0 • n=42 Participants	60.03 years STANDARD_DEVIATION 12.65 • n=42 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	4 Participants n=8 Participants	2 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	9 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	10 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	9 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	27 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	4 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	12 Participants n=8 Participants	1 Participants n=8 Participants	1 Participants n=24 Participants	10 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	32 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	3 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	6 Participants n=42 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	11 Participants n=8 Participants	2 Participants n=8 Participants	1 Participants n=24 Participants	7 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	29 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Region of Enrollment United States	1 participants n=5 Participants	1 participants n=7 Participants	3 participants n=5 Participants	1 participants n=4 Participants	1 participants n=21 Participants	14 participants n=8 Participants	2 participants n=8 Participants	1 participants n=24 Participants	10 participants n=42 Participants	1 participants n=42 Participants	1 participants n=42 Participants	36 participants n=42 Participants

PRIMARY outcome

Timeframe: Cycle 1 (28 days)

Population: A total of 27/27 participants were analyzed: 27/27 participants who received LMP744 in the Escalation phase were analyzed.

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=27 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation Phase: Maximum Tolerated Dose (MTD) of LMP744 (NSC 706744)	—	190 mg/m^2	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, prior to drug administration, 2 minutes before end of infusion; 15 minutes, 30 minutes, and 1, 2, 4, and 6 hours post infusion on Day 1 and prior to start of infusion on Day 2.

Population: A total of 20/36 participants were analyzed: samples from 20/36 participants who had blood collected for pharmacokinetic analyses were analyzed.

AUC is a measure of the serum concentration of LMP744 over time. It is used to characterize drug absorption.

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=1 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=9 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=4 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation & Dose Expansion Phase: Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF) of LMP744 (NSC 706744)	50.7 ng/mL x h	37.1 ng/mL x h	198 ng/mL x h Standard Deviation 54	462 ng/mL x h	1858 ng/mL x h	5752 ng/mL x h Standard Deviation 5251	—	—	4928 ng/mL x h Standard Deviation 2174	—

SECONDARY outcome

Timeframe: Day 1, prior to drug administration, 2 minutes before end of infusion; 15 minutes, 30 minutes, and 1, 2, 4, and 6 hours post infusion on Day 1 and prior to start of infusion on Day 2.

Population: A total of 20/36 participants were analyzed: samples from 20/36 participants who had blood collected for pharmacokinetic analyses were analyzed.

Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=1 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=8 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=4 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation & Dose Expansion Phase: Apparent Half-Life of LMP744 (NSC 706744)	0.52 Hours	0.22 Hours	3.54 Hours Standard Deviation 0.91	4.66 Hours	16.2 Hours	12.59 Hours Standard Deviation 5.11	—	—	5.79 Hours Standard Deviation 3.30	—

SECONDARY outcome

Timeframe: Day(D)1, prior to drug administration, 2 minutes (min) before end of infusion; 15 min., 30 min., and 1, 2, 4, and 6 hours (hr) post infusion on D1. 24 hrs post D2, 3, & 4 start of infusion & 2 min. before end of infusion. 72 hrs post D5 start of infusion.

Time to maximum (Tmax) concentration of LMP744 (NSC 706744).

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=1 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=14 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 n=2 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=10 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation & Dose Expansion Phase: Time to Maximum (Tmax) Concentration of LMP744 (NSC 706744)	1.0 Hours	1.0 Hours	1.1 Hours Interval 1.0 to 2.8	1.0 Hours	1.0 Hours	1.0 Hours Interval 1.0 to 1.0	1.0 Hours Interval 1.0 to 1.0	1.0 Hours	1.0 Hours Interval 1.0 to 1.5	1.0 Hours

SECONDARY outcome

To determine the maximum observed plasma concentration of LMP744, blood samples will be collected from participants and analyzed using a validated liquid chromatography-mass spectrometry (LC-MS) or liquid Chromatography with tandem mass spectrometry (LC-MS-MS) method and calculated by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=1 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=14 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 n=2 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=10 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation & Dose Expansion Phase: Maximum Concentration of LMP744 (NSC 706744)	69.6 ng/mL	48.4 ng/mL	78.1 ng/mL Standard Deviation 49.6	446 ng/mL	433.1 ng/mL	1735.4 ng/mL Standard Deviation 1188.9	861.0 ng/mL Standard Deviation 108.9	839.0 ng/mL	1560.9 ng/mL Standard Deviation 605.5	1160.1 ng/mL

SECONDARY outcome

Timeframe: Day 1 at end of infusion to Day 5 end of infusion.

Population: A total of 20/36 participants were analyzed: samples from 20/36 participants who had blood collected for pharmacokinetic analyses were analyzed.

Percent change in end of infusion drug concentration is a measure of LMP744 (NSC 706744) accumulation in the bloodstream from Day 1 to Day 5.

Outcome measures

Outcome measures
Measure	Treatment Assignment 2: LMP744 (MJ-III65 Hydrochloride) 12mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 12mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	All Participants n=1 Participants Dose Escalation: All participants who received LMP744 at Treatment Assignment 1 (6 mg/m\^2), Treatment Assignment 2 (12 mg/m\^2), Treatment Assignment 3 (24 mg/m\^2), Treatment Assignment 4 (48 mg/m\^2), Treatment Assignment 5 (96 mg/m\^2), Treatment Assignment 6 (190 mg/m\^2), n=9/14, Treatment Assignment 7 (260 mg/m\^2), and Treatment Assignment 7 (260 mg/m\^2) followed by Treatment Assignment 6 (190 mg/m\^2) were assessed for dose-limiting toxicities.	Treatment Assignment 3: LMP744 (MJ-III65 Hydrochloride) 24mg/m^2 n=3 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 24mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 4: LMP744 (MJ-III65 Hydrochloride) 48mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 5: LMP744 (MJ-III65 Hydrochloride) 96mg/m^2 n=1 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 n=9 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 6: LMP744 (MJ-III65 Hydrochloride) 190mg/m^2 Followed by Trmt Assign. 5: 96mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assign. 6:LMP744 190mg/m^2 Foll. by Trmt Assign. 5: 96mg/m^2 Foll. by Trmt Assign. 4: 48mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 190mg/m\^2 intravenous over 1 hour on days 1-5 followed by 96mg/m\^2 intravenous over 1 hour on days 1-5 followed by 48mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Treatment Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 n=2 Participants Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.	Trmt Assignment 7: LMP744 (MJ-III65 Hydrochloride) 260mg/m^2 Followed by Trmt Assign. 6: 190mg/m^2 Participants with metastatic solid tumors that have progressed after one line of therapy, or lymphoma that has progressed after all therapy. LMP744 (MJ-III65 hydrochloride) 260mg/m\^2 intravenous over 1 hour on days 1-5 followed by 190mg/m\^2 intravenous over 1 hour on days 1-5 of each 28 day cycle.
Dose Escalation & Dose Expansion Phase: Percent Change in End of Infusion Concentration of LMP744 (NSC 706744)	33.2 Percent change	8.8 Percent change	6.9 Percent change Standard Deviation 35.6	20.1 Percent change	41.6 Percent change	-14.1 Percent change Standard Deviation 43.0	—	—	25.8 Percent change Standard Deviation 10.4	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Tumor re-staging was performed every 2 cycles for the first year on study then every 3 cycles thereafter until a participant met criteria to be removed from the study; a median of 2 cycles completed and a full range of 0-31 cycles completed.

Population: A total of 35/36 participants were analyzed: tumor measurements from 35/36 participants who had radiologic imaging were analyzed.

Antitumor activity is evaluated using the rate of confirmed objective responses according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (i.e., at least a 30% decrease in the sum of the diameters of target lesions compared to the sum of baseline diameters).